Aliases & Classifications for Keratosis

MalaCards integrated aliases for Keratosis:

Name: Keratosis 12 44 15 17 72
Actinic Keratosis 72
Hyperkeratosis 72

Classifications:



External Ids:

Disease Ontology 12 DOID:161
MeSH 44 D007642
NCIt 50 C34747
UMLS 72 C0022593 C0022602 C0870082

Summaries for Keratosis

Disease Ontology : 12 A skin disease characterized by growth of keratin on the skin or mucous membranes.

MalaCards based summary : Keratosis, also known as actinic keratosis, is related to keratosis follicularis spinulosa decalvans, x-linked and keratosis, seborrheic, and has symptoms including pruritus, exanthema and trichorrhexis invaginata. An important gene associated with Keratosis is MBTPS2 (Membrane Bound Transcription Factor Peptidase, Site 2), and among its related pathways/superpathways are Developmental Biology and Keratinization. The drugs Tazarotene and Nicotinamide have been mentioned in the context of this disorder. Affiliated tissues include skin, testes and t cells, and related phenotypes are Increased vaccinia virus (VACV) infection and cellular

Related Diseases for Keratosis

Diseases related to Keratosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 439)
# Related Disease Score Top Affiliating Genes
1 keratosis follicularis spinulosa decalvans, x-linked 34.8 SAT1 MBTPS2
2 keratosis, seborrheic 34.8 PIK3CA KRT10 FGFR3
3 keratosis follicularis spinulosa decalvans 34.6 SAT1 MBTPS2 LRP1
4 punctate palmoplantar keratoderma 33.1 KRT10 AAGAB
5 mal de meleda 32.8 SLURP1 SERPINB7 KRT1
6 palmoplantar keratoderma, epidermolytic 32.5 KRT9 KRT10 KRT1 FLG
7 dermatosis papulosa nigra 32.1 PIK3CA FGFR3
8 striate palmoplantar keratoderma 31.7 SERPINB7 KRT10 KRT1 DSP DSG1 CTSC
9 alopecia 31.1 MBTPS2 GJA1 DSP
10 acanthoma 31.0 KRT10 KRT1
11 palmoplantar keratosis 30.9 SLURP1 SERPINB7 KRT9 KRT1 GJB2 DSP
12 lichen planus 30.9 KRT10 IVL FLG
13 keratoacanthoma 30.8 KRT10 FLG DSG1
14 nevus, epidermal 30.4 PIK3CA KRT10 FGFR3 ATP2A2
15 eccrine acrospiroma 30.3 KRT9 KRT10
16 cellulitis 30.2 DSP DSG1 ATP2A2
17 corneal degeneration 30.2 SAT1 MBTPS2
18 bullous pemphigoid 30.1 IVL DSP DSG1
19 discoid lupus erythematosus 30.0 KRT10 IVL FLG
20 ainhum 30.0 GJB2 GJA1
21 papilloma 30.0 KRT10 KRT1 IVL FLG FGFR3
22 knuckle pads, leukonychia, and sensorineural deafness 29.9 GJB2 GJA1
23 cardiomyopathy, dilated, with woolly hair and keratoderma 29.9 GJA1 DSP DSG1
24 pseudoainhum 29.7 GJB2 GJA1
25 epidermolytic hyperkeratosis 29.6 KRT9 KRT10 KRT1 FLG
26 ichthyosis 29.5 POMP MBTPS2 KRT10 KRT1 GJB2 FLG
27 pachyonychia congenita 1 29.5 KRT9 KRT10 FLG
28 knuckle pads 29.0 KRT9 GJB2 GJA1
29 skin disease 25.8 SLURP1 KRT9 KRT10 KRT1 IVL GJB2
30 actinic keratosis 12.8
31 keratosis pilaris atrophicans 12.6
32 inverted follicular keratosis 12.6
33 keratosis linearis with ichthyosis congenita and sclerosing keratoderma 12.6
34 keratosis follicularis, dwarfism, and cerebral atrophy 12.5
35 keratosis follicularis spinulosa decalvans, autosomal dominant 12.5
36 keratosis, focal palmoplantar and gingival 12.4
37 vulvar inverted follicular keratosis 12.3
38 vulvar seborrheic keratosis 12.3
39 inflamed seborrheic keratosis 12.3
40 keratosis palmoplantaris striata iii 12.3
41 keratosis palmaris et plantaris with clinodactyly 12.3
42 darier-white disease 12.3
43 keratosis palmoplantaris striata ii 12.2
44 papillon-lefevre syndrome 12.2
45 palmoplantar keratoderma, punctate type ia 12.1
46 haim-munk syndrome 12.1
47 keratosis, familial actinic 12.1
48 onychogryposis, pedal, with keratosis plantaris and coarse hair 12.1
49 circumscribed disseminated keratosis jadassohn lew type 12.1
50 erythrokeratodermia variabilis et progressiva 1 12.0

Comorbidity relations with Keratosis via Phenotypic Disease Network (PDN):


Familial Atrial Fibrillation Heart Disease
Hypertension, Essential Keratosis, Seborrheic

Graphical network of the top 20 diseases related to Keratosis:



Diseases related to Keratosis

Symptoms & Phenotypes for Keratosis

UMLS symptoms related to Keratosis:


pruritus, exanthema, trichorrhexis invaginata

GenomeRNAi Phenotypes related to Keratosis according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased vaccinia virus (VACV) infection GR00249-S 9.62 AAGAB ATP2A2 CTSC DSG1 DSP FGFR3

MGI Mouse Phenotypes related to Keratosis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 9.85 ATP2A2 CTSC DSP FGFR3 GJA1 GJB2
2 growth/size/body region MP:0005378 9.73 ATP2A2 CTSC DSG1 DSP FGFR3 GJA1
3 integument MP:0010771 9.36 ATP2A2 CTSC DSG1 DSP FGFR3 GJA1

Drugs & Therapeutics for Keratosis

Drugs for Keratosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 226)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Tazarotene Approved, Investigational Phase 4 118292-40-3 5381
2
Nicotinamide Approved, Investigational Phase 4 98-92-0 936
3
Metformin Approved Phase 4 657-24-9 4091 14219
4
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
5
Mineral oil Approved, Vet_approved Phase 4 8042-47-5
6
Polymyxin B Approved, Vet_approved Phase 4 1404-26-8
7
Bacitracin Approved, Vet_approved Phase 4 1405-87-4 439542 10909430
8
Hydrogen peroxide Approved, Vet_approved Phase 4 7722-84-1 784
9
Prilocaine Approved Phase 4 721-50-6 4906
10
carbamide peroxide Approved Phase 4 124-43-6
11
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
12
Sorafenib Approved, Investigational Phase 4 284461-73-0 216239 406563
13
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
14
Clobetasol Approved, Experimental, Investigational Phase 4 25122-46-7, 25122-41-2 32798 5311051
15
Apremilast Approved, Investigational Phase 4 608141-41-9 11561674
16
Imiquimod Approved, Investigational Phase 4 99011-02-6 57469
17
Aminolevulinic acid Approved Phase 4 106-60-5 137
18
Salicylic acid Approved, Investigational, Vet_approved Phase 4 69-72-7 338
19
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
20
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
21
Niacin Approved, Investigational, Nutraceutical Phase 4 59-67-6 938
22
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
23
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 22737-96-8, 11103-57-4, 68-26-8 9904001 445354
24
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
25
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
26
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 6221 5280795
27
Protoporphyrin IX Experimental Phase 4 553-12-8
28 Vitamin B9 Phase 4
29 Vitamin B3 Phase 4
30 Vitamin B Complex Phase 4
31 Nicotinic Acids Phase 4
32 Folate Phase 4
33 Hypoglycemic Agents Phase 4
34 Micronutrients Phase 4
35 Hormones Phase 4
36 Trace Elements Phase 4
37 Vitamins Phase 4
38 Nutrients Phase 4
39 Calcium, Dietary Phase 4
40 Bone Density Conservation Agents Phase 4
41 Cyclooxygenase Inhibitors Phase 4
42 Anti-Arrhythmia Agents Phase 4
43 Polymyxins Phase 4
44 Retinol palmitate Phase 4
45 retinol Phase 4
46 Lidocaine, Prilocaine Drug Combination Phase 4
47 Sodium Channel Blockers Phase 4
48 Diuretics, Potassium Sparing Phase 4
49 Vitamin D2 Phase 4
50 Ergocalciferols Phase 4

Interventional clinical trials:

(show top 50) (show all 347)
# Name Status NCT ID Phase Drugs
1 A Randomised Double-blind Parallel-group Study to Evaluate the Long-term Effects of Eryfotona AK-NMSC® Cream in the Treatment of Cancerization Field in Patients With Actinic Keratosis. Unknown status NCT01656226 Phase 4
2 A Double-blind, Randomized, Placebo-controlled, 2-way Crossover Study to Assess the Potential Effect of Topically Applied Imiquimod Cream on Atrial Ectopy in Patients With Actinic Keratosis Unknown status NCT01413763 Phase 4 Imiquimod cream 3.75%;Placebo cream
3 Comparative Intraindividual Study, About the Efficacy and Safety of Treatment of Actinic Keratoses With Photodynamic Therapy Between Acid Methyl Aminolevulinate Cream and Aminolevulinic Gel Unknown status NCT02647151 Phase 4 METHYLAMINOLEVULINATE HYDROCHLORIDE;AMINOLEVULINIC ACID HYDROCHLORIDE
4 An Investigator-Initiated Study to Assess the Safety and Efficacy of Imiquimod 3.75% Cream When Used After Cryotherapy in the Treatment of Hypertrophic Actinic Keratoses (AK) on Dorsal Hands and Forearms Unknown status NCT01229319 Phase 4 Cryotherapy alone to Left arm plus cryotherapy + imiquimod to Right arm;Cryotherapy alone to Left arm plus cryotherapy + imiquimod to Right arm
5 Double-blind Randomized Trial Using Oral Metformin Versus Placebo in the Treatment of Acanthosis Nigricans in Children With Obesity Unknown status NCT02438020 Phase 4 Metformin
6 Efficacy of Combined Fractional Carbon Dioxide Laser and Topical Tazarotene in the Treatment of Psoriatic: Nail Disease a Single-blind, Intrapatient Left-to-right Controlled Study. Unknown status NCT03263624 Phase 4 Tazarotene Cream 0.1%
7 Vehicle-Controlled, Double-Blind Study to Assess the Safety and Efficacy of Imiquimod 5% Cream for the Treatment of Actinic Keratosis on the Upper Extremities Completed NCT00115154 Phase 4 Aldara (imiquimod) cream, 5%
8 Photodynamic Therapy of Actinic Keratosis of the Face and Scalp With and Without Prior Curettage Completed NCT03697590 Phase 4 No curettage;Curettage
9 Comparison of the Efficacy and Tolerability of Solaraze for 3 vs. 6 Months in Patients With Mild to Moderate Actinic Keratosis Located at the Face and Head Completed NCT00204542 Phase 4 Diclofenac;Diclofenac
10 A Pilot Prospective Clinical Trial to Evaluate the Efficacy and Safety of Large-Scale, Field-Directed Topical Therapy of Actinic Keratosis of the Chest With Ingenol Mebutate 0.015% Completed NCT02446223 Phase 4 Inggenol Mebutate 0.015%
11 A Randomized Right/Left Clinical Trial to Evaluate the Use of Biafine Cream Versus Standard Care in Subjects With Actinic Keratosis Post Cryotherapy Completed NCT00695578 Phase 4 Biafine;Polysporin
12 Subject Reported Outcomes on Satisfaction, Safety and Efficacy With Luxerm® in the Field-directed Treatment of Thin or Non-hyperkeratotic and Non-pigmented Actinic Keratosis of the Face or the Scalp Completed NCT03511326 Phase 4 Methyl Aminolaevulinate 16% Cream
13 An Open-Label Study Assessing Subject Satisfaction With A-101 Hydrogen Peroxide Topical Solution, 40% (w/w) Treatment for Seborrheic Keratoses of the Face, Neck, and Decolletage Completed NCT03487588 Phase 4 A-101 Topical Solution
14 Long-term Effects of Aldara® 5% Cream and Solaraze® 3% Gel in the Treatment of Actinic Keratoses on the Face or Scalp With Respect to the Risk of Progression to In-situ and Invasive Squamous Cell Carcinoma Completed NCT01453179 Phase 4 Imiquimod;Diclofenac
15 Long-term Effects of Aldara® 5% Cream and Solaraze® 3% Gel in the Treatment of Actinic Keratoses on the Face or Scalp (LEIDA) Completed NCT00777127 Phase 4 Imiquimod;Diclofenac
16 A Multi-center, OPen, InvEstigator Initiated Phase IV Clinical TRial to Evaluate the Efficacy and SaFety of Ingenol Mebutate Gel 0.015% on Face and Scalp & 0.05% on Trunk and Extremities in KorEan Patient With ACtinic KeraTosis (PERFECT) Completed NCT02716714 Phase 4 ingenol mebutate gel 0.015%;ingenol mebutate gel 0.05%
17 Measuring Adherence To Topical 5-Fluorouracil in a Clinic Population Completed NCT00696488 Phase 4 Fluorouracil 0.5%
18 Gene Expression in Renal Transplant Patients With Field Actinic Keratosis Undergoing Metvix® PDT Completed NCT01000636 Phase 4
19 Evaluating Skin Appearance Following 5-Flourouracil Cream for Treatment of Actinic Keratosis and the Effects of Topical Agents Completed NCT03279328 Phase 4 Topical Steroid Ointment;Skin Barrier Moisturier
20 Open-Label Safety and Pharmacokinetic Study of AldaraTM (Imiquimod) Cream, 5% for One, Two, or Three Treatment Cycles to Surface Areas Greater Than 25 cm2 With Actinic Keratosis Completed NCT00116649 Phase 4 imiquimod cream
21 A Comparison of the Efficacy of Ablative Fractional Laser-assisted Photodynamic Therapy According to the Density of Ablative Laser Channel in the Treatment of Actinic Keratosis Completed NCT03731988 Phase 4 lidocaine/prilocaine (5%) application;MAL application
22 An Open-Label 18-Month Safety Study of Fluorouracil Cream 0.5% for the Treatment of Actinic Keratoses Completed NCT00377273 Phase 4 fluorouracil cream 0.5%
23 Safety and Efficacy of Ingenol Mebutate Gel 0.015% for Treatment of Actinic Keratosis on the Face in Solid Organ Transplant Recipients Completed NCT02866695 Phase 4 ingenol mebutate gel 0.015%
24 A Randomized, Parallel-Group, Vehicle-Controlled, Double-Blind Study of Topical Imiquimod 5% Cream Used as an Adjunct to Cryotherapy in the Management of Actinic Keratoses, With a Long-Term (1 Year) Follow-Up Completed NCT00110682 Phase 4 Imiquimod used as an adjunct to cryotherapy
25 UCI 14-92 / HS#2015-1889: Phase IV Study of Daylight Photodynamic Therapy With Aminolevulinic Acid for Actinic Keratoses Completed NCT03327831 Phase 4 Aminolevulinic Acid
26 Efficacy and Safety of Ingenol Mebutate Gel 0.015% Compared to Diclofenac Sodium Gel 3% in Subjects With Actinic Keratoses on the Face or Scalp Completed NCT02406014 Phase 4 Ingenol Mebutate Gel, 0.015%;Diclofenac sodium gel 3%
27 Daylight Mediated Photodynamic Therapy for Actinic Keratoses: a Multicentre Study Comparing Two Photosensitizers (BF-200 ALA Versus MAL) Completed NCT02464709 Phase 4 Aminolevulinic Acid;Methyl 5-aminolevulinate
28 A Randomized, Open-label, Assessor-blinded, Split-face Study of Imiquimod 5% Cream Applied After Cryotherapy of Actinic Keratoses Completed NCT00774787 Phase 4 imiquimod 5% cream
29 An Investigator-Initiated Study to Assess the Safety and Efficacy of Ingenol Mebutate 0.05% Gel When Used After Cryotherapy in the Treatment of Hypertrophic Actinic Keratoses (AK) on Dorsal Hands Completed NCT02251652 Phase 4 Ingenol Mebutate
30 Treatment of AKs With Daylight-PDT: Comparing Two Photosensitizers (BF-200 ALA and MAL) Completed NCT01893203 Phase 4 BF-200 ALA cream;MAL cream
31 Prospective, Controlled and Monocentric Study to Evaluate the Effects of Topical 3% Diclofenac in 2.5% Hyaluronic Acid Gel on Tumor Metabolism in the Treatment of Actinic Keratoses in Immunocompetent and Immunocompromised Patients Completed NCT01935531 Phase 4 3% diclofenac in 2.5% hyaluronic acid gel
32 A Randomized, Evaluator-blinded, Bilateral Comparison of the Treatment of Facial Actinic Keratoses Using Combination Microneedling and Photodynamic Therapy With Aminolevulinic Acid and Blue Light Versus Photodynamic Therapy With Aminolevulinic Acid and Blue Light Using Two Different Incubation Times Completed NCT02622594 Phase 4 Aminolevulinic Acid (ALA)
33 Comparison of Efficacy and Safety of Psoriatic Nails Treatment Between by Intralesional 0.1%Triamcinolone Injection and Topical 0.05%Clobetasol Propionate Ointment Completed NCT01703325 Phase 4 0.1% triamcinolone , 0.05% clobetasol propionate ointment
34 The Effect of Urea Cream on Sorafenib-associated Hand-Foot Skin Reaction in Patients With Korean Hepatocellular Carcinoma Patients: Multicenter, Prospective Randomized Double-Blind Controlled Study Completed NCT03212625 Phase 4 Urea Cream 20%;Placebos
35 Role of Vitamin D in Secondary Prevention of Knee Osteoarthritis: A Double-blind Randomized Controlled Trial Completed NCT00599807 Phase 4
36 Clinical Trial of the Effectiveness of Chlorhexidine Gluconate 0.125 % Compared With Sterile Deionized Water in the Closure of Diabetic Foot Ulcer Syndrome. Completed NCT02097615 Phase 4
37 A Randomised Double Blind, Placebo Controlled Study of the Efficacy of Topical Menthol for Pain Relief During Topical Photodynamic Therapy Recruiting NCT02984072 Phase 4 Menthol;Aqueous Cream
38 Aminolevulinic Acid-photodynamic Therapy for Facial Actinic Keratosis Treatment and Prevention: A Long-term (3 Years) Follow-up of Prospective, Randomized, Multicenter-clinical Trial Recruiting NCT03642535 Phase 4 ALA
39 Standard Management and Chlorhexidine Gluconate Solution at 0.125% Versus Standard Management and Physiological Saline Sterile Solution for Healing Grade IIB Ulcers in Diabetic Foot Syndrome: Clinical Trial Recruiting NCT03209466 Phase 4 Chlorhexidine gluconate at 0.125%;Placebo Comparator with physiological saline sterile solution
40 Topical Ingenol Mebutate Versus 5% 5-fluorouracil Versus 5% Imiquimod Versus Photodynamic Therapy in Treatment of Actinic Keratosis: a Multi-centre Randomized Efficacy and Cost-effectiveness Study Active, not recruiting NCT02281682 Phase 4 Imiquimod;5-fluorouracil;Ingenol mebutate
41 A Phase 4 Trial Comparing the Cumulative Incidence of SCC After Treatment With Ingenol Mebutate and Imiquimod for Multiple Actinic Keratoses on Face and Scalp. A Multi-centre, Randomised, Two-arm, Open Label, Active-controlled, Parallel Group, 36-month Trial Active, not recruiting NCT01926496 Phase 4 Ingenol Mebutate Gel, 0.015%;Imiquimod Cream, 5%
42 A Randomized Study to Evaluate the Efficacy of Ingenol Mebutate on Actinic Keratoses and Field Cancerization Compared to Cryotherapy Active, not recruiting NCT02990221 Phase 4 Ingenol mebutate
43 Prospective, Randomized, Controlled, Multicenter, Two-armed, Study Comparing Daylight Photodynamic Therapy Using MAL With Cryosurgery for the Treatment and Prophylaxis of Actinic Keratoses in Photodamaged Skin of the Face Active, not recruiting NCT02736760 Phase 4 Daylight photodynamic therapy using Methylaminolevulinate (MAL)
44 An Investigator Initiated Open Label Study Evaluating the Efficacy and Tolerability of Oral Apremilast for the Treatment of Nail Psoriasis Enrolling by invitation NCT03022617 Phase 4 Apremilast
45 An Exploratory, Open-label Study of Sequential Field-directed Treatment of Actinic Keratoses of the Face With Imiquimod 3.75% Cream Followed by Photodynamic Therapy Terminated NCT01203878 Phase 4 Photodynamic therapy;Imiquimod
46 Topical Imiquimod 5% Cream Therapy Versus Photodynamic Therapy With Methyl-aminolaevulinate 16% Cream of Actinic Keratoses in Organ Transplant Recipients Terminated NCT01538901 Phase 4 imiquimod 5% cream
47 Efficacy and Safety of Salkera Emollient Foam in the Treatment of Moderate to Severe Keratosis Pilaris, a Prospective Study Terminated NCT00944216 Phase 4 Salkera Emollient Foam
48 Phase III Comparative Study About the Use of 5% 5-fluorouracil Cream Versus Its Utilization as Agent for Sequential Superficial Peeling in the Treatment of Advanced Photoaging Unknown status NCT01405144 Phase 3 5-fluoruracil
49 A RANDOMIZED, DOUBLE BLIND, MULTI-CENTER CLINICAL STUDY TO TEST THE SAFETY AND EFFICACY OF T4N5 LIPOSOME LOTION ON PATIENTS WITH XERODERMA PIGMENTOSUM IN THE PROTECTION AGAINST ACTINIC KERATOSES Unknown status NCT00002811 Phase 3 liposomal T4N5 lotion
50 A Monocentric, Single-Blind, Randomized, Placebo-Controlled Study of the Safety and Efficacy of the Topical Drug Acnase Creme in the Treatment of Acne Vulgaris I and II Unknown status NCT00877409 Phase 3 Benzoyl Peroxide 5% and Sulphur 2%;Vehicle of Acnase

Search NIH Clinical Center for Keratosis

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Diclofenac
Diclofenac Potassium
Diclofenac Sodium
Fluorouracil
Masoprocol

Cochrane evidence based reviews: keratosis

Genetic Tests for Keratosis

Anatomical Context for Keratosis

MalaCards organs/tissues related to Keratosis:

41
Skin, Testes, T Cells, Breast, Liver, Bone, Tongue

Publications for Keratosis

Articles related to Keratosis:

(show top 50) (show all 9677)
# Title Authors PMID Year
1
Proper management of suspicious actinic cheilitis. 38
31032237 2019
2
The 308-nm excimer laser treatment does not increase the risk of skin cancer in patients with vitiligo: A population-based retrospective cohort study. 38
30849210 2019
3
Imiquimod 3.75% for field-directed therapy of actinic keratosis: results of a prospective case-series study in Greece. 38
30779341 2019
4
Imaging of temporal bone inflammations in children: a pictorial review. 38
31321462 2019
5
Oral Epithelial Dysplasia and Premalignancy. 38
30887394 2019
6
Gene expression profiling of lichenoid dermatitis immune-related adverse event from immune checkpoint inhibitors reveals increased CD14+ and CD16+ monocytes driving an innate immune response. 38
30883858 2019
7
Onychomatricoma Micropapilliferum, a New Variant of Onychomatricoma: Clinical, Dermoscopical, and Histological Correlations (Report of 4 Cases). 38
31436573 2019
8
Atrophic and hypertrophic photoaging: Clinical, histologic, and molecular features of 2 distinct phenotypes of photoaged skin. 38
30954583 2019
9
Seborrheic Keratosis or Squamous Carcinoma? Clinical Examination versus Biopsy: The Importance of Criticism. 38
31120423 2019
10
A previously undescribed cutaneous paraneoplastic syndrome in a cat with thymoma. 38
30908751 2019
11
Intralesional injection of vitamin D3 versus zinc sulfate 2% in treatment of plantar warts: a comparative study. 38
31415213 2019
12
Conceptual, statistical and clinical interpretation of results from: Cryosurgery combined with topical interventions for actinic keratosis: reply from the authors. 38
31021410 2019
13
A case of keratosis pilaris rubra in a 17th century portrait? 38
30851215 2019
14
Epidermolytic Hyperkeratosis: A Challenging Pathology for Clinical Correlation 38
31290641 2019
15
Novel application of anterior segment optical coherence tomography for periocular imaging. 38
31358140 2019
16
Palisaded Encapsulated (Solitary Circumscribed) Neuroma: A Review of 30 Cases. 38
30834800 2019
17
Somatic mutations in kinetochore gene KNSTRN are associated with basal proliferating actinic keratoses and cutaneous squamous cell carcinoma. 38
30972880 2019
18
Support Vector Machine Classification of Nonmelanoma Skin Lesions Based on Fluorescence Lifetime Imaging Microscopy. 38
31314502 2019
19
The White Lesion, Hyperkeratosis, and Dysplasia. 38
31078307 2019
20
Zombie Cells, Composite Cells of Fungal-Human Keratinocytes of Plantar Hyperkeratosis-Like Lesions. 38
31376042 2019
21
Review of 52 cases with Hailey-Hailey disease identified 25 novel mutations in Chinese Han population. 38
31435946 2019
22
A broad range of symptoms in allgrove syndrome: single center experience in Southeast Anatolia. 38
31435881 2019
23
Dermoscopy of hyperkeratosis lenticularis perstans (Flegel disease). 38
30802320 2019
24
Verruciform Xanthoma of the Oral Mucosa: A Series of Eight Typical and Three Anomalous Cases. 38
30727785 2019
25
A novel mutation in MBTPS2 causes ichthyosis follicularis, alopecia, and photophobia syndrome. 38
31215178 2019
26
Clinical outcomes of BRAF plus MEK inhibition in melanoma: A meta-analysis and systematic review. 38
31393083 2019
27
Ginsenoside compound K ameliorates imiquimod-induced psoriasis-like dermatitis through inhibiting REG3A/RegIIIγ expression in keratinocytes. 38
31182284 2019
28
Foot care in Epidermolysis bullosa: Evidence-based Guideline. 38
31397882 2019
29
Lichenoid granulomatous dermatitis revisited: A retrospective case series. 38
31378565 2019
30
Risk-Aware Machine Learning Classifier for Skin Lesion Diagnosis. 38
31426482 2019
31
Usefulness of narrow band imaging with magnifying endoscopy for the differential diagnosis of cancerous and noncancerous laryngeal lesions. 38
30843628 2019
32
Photodynamic therapy for the prevention and treatment of Actinic Keratosis/Squamous cell carcinoma in solid organ transplant recipients: A systematic review and meta-analysis. 38
31394005 2019
33
5-aminolaevulinic acid nanoemulsion is more effective than methyl-5-aminolaevulinate in daylight photodynamic therapy for actinic keratosis: a nonsponsored randomized double-blind multicentre trial. 38
30329163 2019
34
Conceptual, statistical and clinical interpretation of results from: Cryosurgery combined with topical interventions for actinic keratosis: a systematic review and meta-analysis. 38
30767194 2019
35
Split-face study comparing conventional MAL photodynamic therapy in multiple actinic keratosis with complete time vs. half-time red light LED conventional illumination. 38
30868672 2019
36
Field cancerization therapy with ingenol mebutate contributes to restoring skin-metabolism to normal-state in patients with actinic keratosis: a metabolomic analysis. 38
31395965 2019
37
Long-term clinical outcomes of imiquimod 5% cream versus diclofenac 3% gel for actinic keratosis on the face or scalp: a pooled analysis of two randomized controlled trials. 38
31407414 2019
38
A comparison of the efficacy of ablative fractional laser-assisted photodynamic therapy according to ablative depth for actinic keratosis: A single-blinded, randomized, comparative, prospective study. 38
30690046 2019
39
Yonder: Obesity communication, opioid deprescribing, actinic keratosis, and artificial intelligence. 38
31249088 2019
40
Clinical and molecular analysis in Papillon-Lefèvre syndrome. 38
31282082 2019
41
Clinical Experience With 40% Hydrogen Peroxide Topical Solution for the Treatment of Seborrheic Keratosis 38
31336413 2019
42
Value of Dermoscopy in a Population-Based Screening Sample by Dermatologists. 38
31384493 2019
43
Dermatopathological characteristics of dermatofibromas from dermatoscopic clues. 38
31264200 2019
44
Dermatoses in parkinsonism: the importance of multidisciplinary follow-up. 38
31340306 2019
45
Detection and genomic characterization of Bovine papillomavirus isolated from Chinese native cattle. 38
31269541 2019
46
Animal Model of Chronic Tympanic Membrane Perforation. 38
31260172 2019
47
Gain of function p.E138A alteration in Card14 leads to psoriasiform skin inflammation and implicates genetic modifiers in disease severity. 38
31323190 2019
48
Nail Changes in Sézary Syndrome: A Single-Center Study and Review of the Literature. 38
30917680 2019
49
Salivary Tumour Necrosis Factor-α as a Biomarker in Oral Leukoplakia and Oral Squamous Cell Carcinoma. 38
31350970 2019
50
Effects of Corynebacterium bovis on Engraftment of Patient-derived Chronic Myelomonocytic Leukemia Cells in NSGS Mice. 38
31349880 2019

Variations for Keratosis

Expression for Keratosis

Search GEO for disease gene expression data for Keratosis.

Pathways for Keratosis

GO Terms for Keratosis

Cellular components related to Keratosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 intermediate filament GO:0005882 9.43 KRT9 KRT10 KRT1 GJA1 FLG DSP
2 connexin complex GO:0005922 9.37 GJB2 GJA1
3 lateral plasma membrane GO:0016328 9.33 GJB2 GJA1 DSG1
4 fascia adherens GO:0005916 9.26 GJA1 DSP
5 cornified envelope GO:0001533 9.1 KRT10 KRT1 IVL FLG DSP DSG1
6 cytosol GO:0005829 10.1 SAT1 POMP PIK3CA KRT9 KRT10 KRT1

Biological processes related to Keratosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 keratinization GO:0031424 9.63 KRT9 KRT10 KRT1 IVL DSP DSG1
2 epidermis development GO:0008544 9.58 KRT9 DSP ATP2A2
3 keratinocyte differentiation GO:0030216 9.56 KRT10 IVL FLG DSP
4 decidualization GO:0046697 9.48 GJB2 GJA1
5 establishment of skin barrier GO:0061436 9.46 KRT1 FLG
6 intermediate filament organization GO:0045109 9.43 KRT9 DSP
7 gap junction assembly GO:0016264 9.37 GJB2 GJA1
8 peptide cross-linking GO:0018149 9.35 KRT10 KRT1 IVL FLG DSP
9 epididymis development GO:1905867 9.32 GJB2 GJA1
10 cornification GO:0070268 9.17 KRT9 KRT10 KRT1 IVL FLG DSP

Molecular functions related to Keratosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 gap junction channel activity GO:0005243 9.16 GJB2 GJA1
2 structural molecule activity GO:0005198 9.13 KRT10 FLG DSP
3 structural constituent of epidermis GO:0030280 8.8 KRT10 KRT1 FLG

Sources for Keratosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....